Bayer Australia

60 PBAC submissions on file, active 2006–2024. 68% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Darolutamide
  Oncology · Recommended with restriction · 2022$59M
• Aflibercept
  Ophthalmology · Recommended · 2025other sponsor
• Rivaroxaban
  Cardiovascular · Noted · 2024—
• Sorafenib
  Oncology · Not recommended · 2015—
• Regorafenib
  Oncology · Recommended with restriction · 2021—
• Larotrectinib
  Oncology · Not recommended · 2024—
• Riociguat
  Cardiovascular · Deferred · 2016—
• Levonorgestrel
  Women's health · Recommended with restriction · 2019—
• Drospirenone with ethinylestradiol
  Women's health · Not recommended · 2024—
• Finerenone
  Endocrinology · Recommended with restriction · 2023—
• Vericiguat
  Cardiovascular · Recommended with restriction · 2022—
• Dienogest
  Women's health · Recommended with restriction · 2024—
• Fludarabine phosphate
  Haematology · Recommended with restriction · 2008—
• Radium-223 dichloride
  Oncology · Recommended with restriction · 2017—
• Sorafenib tosylate
  Oncology · Not recommended · 2008—

Therapy area mix

Activity by year

2006 (1) · 2008 (3) · 2009 (1) · 2012 (4) · 2013 (5) · 2014 (9) · 2015 (6) · 2016 (1) · 2017 (1) · 2018 (3) · 2019 (4) · 2020 (4) · 2021 (4) · 2022 (5) · 2023 (1) · 2024 (8)

Rejection patterns

Across 15 Not recommended decisions on file.

• 2×no economic analysis provided
• 1×ICER unacceptably high in context of recent visual acuity medicines
• 1×concerns over long-term efficacy (recurrence of oedema with 'as needed' dosing)
• 1×inadequate justification for co-dependence with OCT
• 1×model duration of 35 years unlikely to be reflective of real-world experience for elderly PBS population